Menu Search
Equities

BioMarin Pharmaceutical Inc

BMRN:MEX

BioMarin Pharmaceutical Inc

Actions
  • Price (MXN)1,700.00
  • Today's Change0.00 / 0.00%
  • Shares traded2.00
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Aug 20 2024 12:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year BioMarin Pharmaceutical Inc grew revenues 15.42% from 2.10bn to 2.42bn while net income improved 18.43% from 141.56m to 167.65m.
Gross margin78.95%
Net profit margin11.71%
Operating margin11.81%
Return on assets4.74%
Return on equity6.25%
Return on investment5.49%
More ▼

Cash flow in USDView more

In 2023, BioMarin Pharmaceutical Inc did not generate a significant amount of cash. However, the company earned 159.26m from its operations for a Cash Flow Margin of 6.58%. In addition the company used 111.24m on investing activities and also paid 18.73m in financing cash flows.
Cash flow per share2.15
Price/Cash flow per share28.66
Book value per share28.41
Tangible book value per share26.01
More ▼

Balance sheet in USDView more

BioMarin Pharmaceutical Inc has a Debt to Total Capital ratio of 9.90%, a lower figure than the previous year's 12.10%.
Current ratio4.27
Quick ratio2.62
Total debt/total equity0.1098
Total debt/total capital0.099
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.